Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
This is an open-label, multi-center, phase Ⅱ study. This study will evaluate the efficacy and safety of pembrolizumab in combination with disitamab vedotin in subject with HER2-expressing metastatic Colorectal Cancer (mCRC).
Colorectal Neoplasms
DRUG: Pembrolizumab|DRUG: Disitamab vedotin
Objective response rate (ORR), proportion of patients with complete and partial remission in the best efficacy, 24 months after the last subject participating in
Disease control rate (DCR), the best efficacy is the proportion of patients with complete remission, partial remission and stable disease, 24 months after the last subject participating in|Progression free survival time (PFS), time from the start of medication to the initial progression of the disease, 24 months after the last subject participating in|Overall survival (OS), time from the start of medication to death, 36 months after the last subject participating in
This is an open-label, multi-center, phase Ⅱ study. This study will evaluate the efficacy and safety of pembrolizumab in combination with disitamab vedotin in subject with HER2-expressing metastatic Colorectal Cancer (mCRC).